Optimal revascularization in diabetes after the FREEDOM trial: Were the controversies finally settled?

Cardiology Journal

Volumn 20, Issue 4, 2013, Pages 331-336

  Tenenbaum, Alexander ^a,b,c   Fisman, Enrique Z ^b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Cardiovascular Diabetology Research Foundation   (Israel)

Author keywords

Coronary artery disease; Diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; EVEROLIMUS; INSULIN; PACLITAXEL; PRASUGREL; RAPAMYCIN; TICAGRELOR;

ATHEROGENESIS; BARE METAL STENT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY STENT; DEVICE SAFETY; DIABETES MELLITUS; DRUG ELUTING STENT; HEART INFARCTION; HOSPITAL READMISSION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; MORTALITY; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEAT PROCEDURE; REVIEW; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG-ELUTING STENTS; HUMANS; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84885213501     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.2013.0090     Document Type: Review

References (40)

1. Farkouh ME, Domanski M, Sleeper LA et al. Strategies for Multi-vessel Revascularization in Patients with Diabetes. N Engl J Med, 2012 [Epub ahead of print].
2. Preis SR, Hwang SJ, Coady S et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation, 2009; 119: 1728-1735.
3. Groot MW, Head SJ, Bogers AJ, Kappetein AP. Coronary revascularization in diabetic patients. A focus on the 3-year SYNTAX trial outcomes. Herz, 2012; 37: 281-286.
4. Fox CS, Coady S, Sorlie PD et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation, 2007; 115: 1544-1550.
5. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular isease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation, 2003; 108: 1527-1532.
6. Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol, 2003; 41: 1071-1077.
7. An X, Yu D, Zhang R et al. Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study. Cardiovasc Diabetol, 2012; 11: 71.
8. Ferreiro JL, Angiolillo DJ. Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. Curr Pharm Des, 2012; 18: 5273-9523.
9. Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coro-nary revascularization in diabetic patients. Eur Heart J, 2011; 32: 2748-2757.
10. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res, 1998; 37: 586-600.
11. Kassaian SE, Goodarzynejad H, Boroumand MA et al. Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. Cardiovasc Diabetol, 2012; 11: 82.
12. Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res, 2010; 7: 251-259.
13. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol, 2002; 1: 1.
14. Gilbert J, Raboud J, Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care, 2004; 27: 990-994.
15. Blöndal M, Ainla T, Marandi T, Baburin A, Eha J. Sex-specific outcomes of diabetic patients with acute myocardial infarction who have undergone percutaneous coronary intervention: a register linkage study. Cardiovasc Diabetol, 2012; 11: 96.
16. Stettler C, Allemann S, Wandel S et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ, 2008; 337: a1331.
17. Garg P, Normand SL, Silbaugh TS, Wolf RE et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: Results from the Massachusetts Data Analysis Center Registry. Circulation, 2008; 118: 2277-2285.
18. Saucedo JF. Antiplatelet therapy for patients with diabetes mellitus and acute coronary syndrome. Prim Care Diabetes, 2012; 6: 167-177.
19. James S, Angiolillo DJ, Cornel JH et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: A substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J, 2010; 31: 3006-3016.
20. Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: From aspirin to the present day. Drugs, 2012; 72: 2087-2116.
21. Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel: Thrombolysis in Myocardial Infarction 38. Circulation, 2008; 118: 1626-1636.
22. Hlatky MA, Boothroyd DB, Bravata DM et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet, 2009; 373: 1190-1197.
23. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA, 2005; 293: 1501-1508.
24. Kapur A, Hall RJ, Malik IS et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. One-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol, 2010; 55: 432-440.
25. Mack MJ, Banning AP, Serruys PW et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann Thorac Surg, 2011; 92: 2140-2146.
26. Banning AP, Westaby S, Morice MC et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol, 2010; 55: 1067-1075.
27. Sianos G, Morel MA, Kappetein AP et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention, 2005; 1: 219-227.
28. Hannan EL, Wu C, Walford G et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med, 2008; 358: 331-341.
29. Przybysz-Zdunek B, Ploch M, Pluta W, Dada M, Opolski G. All cause readmission and repeat revascularization after percutaneous coronary intervention. Cardiol J, 2012; 19: 174-179.
30. Hlatky MA. Compelling Evidence for Coronary-Bypass Surgery in Patients with Diabetes. N Engl J Med, 2012 [Epub ahead of print].
31. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet, 2008; 372: 1163-1173.
32. Kedhi E, Gomes ME, Lagerqvist B et al. Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: Insights from a nationwide coronary intervention register. J Am Coll Cardiol Cardiovasc Interv, 2012; 5: 1141-1149.
33. Tzifos V, Gatsis A, Gerasimou A, Chatzis D, Theodorakis G. Acute and long term results of unprotected left main stenting using drug eluting stents. Cardiol J, 2011; 18: 165-170.
34. Grube E, Chevalier B, Guagliumi G et al. The SPIRIT V diabetic study: A randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs. the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J, 2012; 163: 867-875.
35. Kereiakes DJ, Sudhir K, Hermiller JB et al. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. J Am Coll Cardiol Cardiovasc Interv, 2010; 3: 1229-1239.
36. Sheehy A, Hsu S, Bouchard A et al. Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries. Cardiovasc Diabetol, 2012; 11: 75.
37. Sedlis SP, Morrison DA, Lorin JD et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: Outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol, 2002; 40: 1555-1566.
38. Yan Q, Changsheng M, Shaoping N et al. Percutaneous treatment with drug-eluting stent vs. bypass surgery in patients suffering from chronic stable angina with multivessel disease involving significant proximal stenosis in left anterior descending artery. Circ J, 2009; 73: 1848-1855.
39. Green L. Technoculture: From Alphabet to Cybersex. Allen & Unwin, Sydney, Australia 2002.
40. Garg S, Serruys PW. An update on drug-eluting stents. Curr Treat Options Cardiovasc Med, 2012 [Epub ahead of print].